PTGS2 and major depressive disorder: Interestingly, 5-lipoxygenase, the target of FLAP activation, has been implicated in aging and neurodegenerative diseases [40], as well as other psychiatric disorders [41], including anxiety and depression, which are frequently co-morbid conditions of autism, while a COX-2 inhibitor, celecoxib, has been shown to have therapeutic effects in major depression [42], further suggesting a role for inflammatory processes in psychiatric disease.